WHO Medicines Strategy: Framework for Action in Essential Drugs and Medicines Policy - 2000

WHO Medicines Strategy: Framework for Action in Essential Drugs and Medicines Policy - 2000 - 2003
(2000; 81 pages) [French]

Índice de contenido

	Acknowledgements
	Abbreviations, Acronyms & WHO Regions
	Highlights - WHO Medicines Strategy: 2000 - 2003
	1. The Impact of Essential Drugs
		1.1. Substantial progress has been made
		1.2 Unfinished agenda and new challenges
	2. Strategic Directions
		2.1. WHO strategic directions
		2.2 WHO Medicines Strategy: 2000 - 2003
		2.3 Health technology and pharmaceuticals
	3. Core Functions Improving Health Through Knowledge, Advocacy and Partnership
	4. Country Work - Why and How?
		4.1 Country work in context
		4.2 How WHO works with countries on medicines
		4.3 Types of WHO support
	5. Framework for Action: Objectives and Expected Outcomes for 2000 - 2003
		5.1 Policy: Ensure commitment of all stakeholders to national drug policies, to coordinated implementation, and to monitoring policy impact
		5.2 Access: Ensure equitable availability and affordability of essential drugs, with an emphasis on diseases of poverty
		5.3 Quality and safety: Ensure the quality, safety and efficacy of all medicines by strengthening and putting into practice regulatory and quality assurance standards
		5.4 Rational use: Ensure therapeutically sound and cost-effective use of drugs by health professionals and consumers
	6. Monitoring Progress
		6.1 Monitoring, evaluation and indicators
		6.2 Country progress indicators for the WHO Medicines Strategy
		6.3 Indicator values for the WHO Medicines Strategy
		6.4 Improving the monitoring/evaluation process and tools
	References and Notes

References and Notes

1.	The terms “drug”, “medicine”, “pharmaceutical”, and “pharmaceutical product” are used interchangeably, except in Section 2.3, where “pharmaceuticals” is used in its broader sense and includes other products such as vaccines, and biological products.
2.	World Health Organization. The World Health Report 1999. Making a Difference. Geneva, World Health Organization, 1999.
3.	World Health Organization. The Use of Essential Drugs. 6^thReport of the Expert Committee. Geneva, World Health Organization, 1995 (WHO Technical Report Series, No. 850).
4.	Govindaraj R, Chellaraj G, Murray CJL. Health expenditures in Latin America and the Caribbean. Social Science and Medicine, 1997, 44: 157 - 170.
5.	World Health Organization. Health Reform and Drug Financing. Selected Topics. Geneva, World Health Organization, 1998 (Health Economics and Drugs DAP Series No. 6. Document reference WHO/DAP/98.3.).
6.	World Drug Situation database.
7.	World Health Organization. Guide to Good Prescribing. Geneva, World Health Organization, 1994 (document reference WHO/DAP/94.11).
8.	World Health Organization. Revised Drug Strategy. WHO’s Work in Pharmaceuticals and Essential Drugs. Geneva, World Health Organization, 1998 (document reference EB/RDS/RC/1).
9.	Murray CJL, Lopez AD. Global Health Statistics, Volume II. Cambridge, MA, Harvard School of Public Health on behalf of the World Health Organization and The World Bank, 1996.
10.	Guillot M, Gwatkin DR. The Burden of Disease among the Global Poor, Current Situation, Future Trends, and Implications for Strategy. Washington DC, Human Development Network, The World Bank, 1999.
11.	World Health Organization. Progress of WHO Member States in Developing National Drug Policies and in Revising Essential Drugs Lists. Geneva, World Health Organization, 1998 (document reference WHO/DAP/98.7).
12.	World Health Organization. Action Programme on Essential Drugs. Report of the Biennium 96 - 97. Geneva: World Health Organization, 1998 (document reference WHO/DAP/MAC(10)98.4).
13.	World Health Organization. Comparative Analysis of National Drug Policies. Geneva, World Health Organization, 1997 (DAP Research Series No. 25. Document reference WHO/DAP/97.6.).
14.	Hogerzeil HV. Promoting rational prescribing. British Journal of Clinical Pharmacology, 1995, 39: 1 - 6.
15.	Lansang MA et al. Purchase of antibiotics without prescription in Manila, The Philippines. Inappropriate choices and doses. Journal of Clinical Epidemiology, 1990, 43(1): 61 - 67.
16.	Dua V, Kunin CM, White LV. The use of antimicrobial drugs in Nagpur, India. A window on medical care in a developing country. Social Science and Medicine, 1994, 38(5): 717 - 724.
17.	Hogerzeil HV et al. Field test for rational drug use in twelve developing countries. The Lancet, 4 December 1993: 1408 - 1410.
18.	Homedes N, Ugalde A. Patients’ compliance with medical treatments in the third world. What do we know? Health Policy and Planning, 1993, 8(4): 291 - 314.
19.	World Health Organization. A Corporate Strategy for the WHO Secretariat. Report by the Director-General. Geneva, World Health Organization, 1999 (document reference EB105/3).
20.	The original revised drug strategy was adopted at the 1986 World Health Assembly. See World Health Assembly Resolution 39.27.
21.	World Health Organization. Health for All in the 21^stCentury. Geneva, World Health Organization, 1998 (document reference A51/5).
22.	World Health Organization. Towards a Strategic Agenda for the WHO Secretariat. Statement by the Director-General to the Executive Board at its 105th Session. Geneva, World Health Organization, 2000 (document reference EB105/2).
23.	World Health Organization. The World Health Report 2000. Health Systems: Improving Performance. Geneva, World Health Organization, 2000.
24.	World Health Organization. Strategic Plan 2000 - 2003: Health Technology and Pharmaceuticals. Geneva, World Health Organization, 2000(document reference WHO/HTP/00.01).
25.	World Health Organization. Speech of Director-General Dr Gro Harlem Brundtland to Meeting of the Ad Hoc Committee on the Revised Drugs Strategy, Geneva, 13 October 1998 (document reference EB/RDS/1/2).
26.	World Health Organization. Working In and With Countries. Report by the Director-General. Geneva, Switzerland, 1999 (document reference EB105/7).
27.	Further detail for proposed activities can be found in the workplans of the Department of Essential Drugs and Medicines Policy at WHO Headquarters and the Regional Offices.
28.	World Health Organization. Guidelines for Developing National Drug Policies. Geneva, World Health Organization, 1988.
29.	World Health Organization. Progress of WHO Member States in Developing National Drug Policies and in Revising Essential Drugs Lists. Geneva, World Health Organization, 1998 (document reference WHO/DAP/98.7).
30.	Poverty and health. Report by the Director-General to the Executive Board. Geneva, World Health Organization, 1999 (document reference EB105/5).
31.	Speech of Director-General Dr Gro Harlem Brundtland to UN Commission on the Status of Women, New York, 3 March 1999. Accessible at: http://www.who.int/director-general/speeches/english/19990303_un_commission_women.html.
32.	World Health Organization. Public - private Roles in the Pharmaceutical Sector. Geneva, World Health Organization, 1997 (Health Economics and Drugs DAP Series No. 5. Document reference WHO/DAP/97.12.).
33.	World Health Organization. Progress Towards Health for All. Statistics of Member States. Geneva, World Health Organization, 1994 (document reference WHO/HST/GSP/94.1).
34.	Rational drug selection is further elaborated in Section 5.4; relevant activities will contribute to meeting both the access objective and the rational use objective.
35.	Pécoul B et al. Access to essential drugs in poor countries. A lost battle? Special communication. Journal of the American Medical Association 1999, 281(4): 361 - 367.
36.	See also Section 5.4.
37.	World Health Organization. Globalization and Access to Drugs. Perspectives on the WTO/TRIPS Agreement. Geneva, World Health Organization, 1998 (Health Economics and Drugs DAP Series No. 7, revised. Document reference WHO/DAP/98.9.).
38.	World Health Organization. Removing Obstacles to Healthy Development. Report on Infectious Diseases. Geneva, World Health Organization, 1999 (document reference WHO/CDS/99.1).
39.	Sen A. Searching for a Deeper Understanding of Development. 1999 World Health Assembly keynote address.
40.	World Health Organization. Globalization, Patents and Drugs. An Annotated Bibliography. Geneva, World Health Organization, 1999 (Health Economics and Drugs, EDM Series No. 9. Document reference WHO/EDM/PAR/99.6.).
41.	World Health Organization. Global Comparative Pharmaceutical Expenditures with Related Reference Information. Geneva, World Health Organization, 2000 (Health Economics and Drugs EDM Series No. 3. Document reference EDM/PAR/2000.2.).
42.	Scholtz M. International trade agreements and public health: WHO’s role. Presentation at conference: Increasing Access to Essential Drugs in a Globalized Economy, Amsterdam, 25 - 26 November 1999.
43.	World Health Organization. Quality Assurance of Pharmaceuticals. A Compendium of Guidelines and Related Materials. Volume 1. Geneva, World Health Organization, 1997.
44..	Opening remarks of Director-General Dr Gro Harlem Brundtland to Brazilian Parliamentary Commission on Investigation of Medicines, Brasilia, 4 April 2000. Accessible at: http://www.who.int/director-general/speeches/2000/20000404_brasilia.html
45.	Caves RE, Whinston MD, Hurtwitz MA. Patent Expiration, Entry and Competition in the U.S. Pharmaceutical Industry. 1991 (Brooking Papers on Economic Activity: Microeconomics.)
46.	Samb B. Travel report for UNAIDS, 2000.
47.	Diarra K, Coulibaly S. Financing of recurrent health costs in Mali. Health Policy and Planning, 1990, 5(2): 126 - 138.
48.	UNICEF. UNICEF-Bamako Technical Report No. 35; Bangladesh National Accounts 1996/97
49.	World Health Organization. Essential Drugs Monitor Nos. 25 and 26. Geneva, World Health Organization, 1998.
50.	Management Sciences for Health/World Health Organization. Managing Drug Supply, 2nd edition. Connecticut, Kumarian Press, 1997.
51.	World Health Organization. Operational Principles for Good Pharmaceutical Procurement. Geneva, World Health Organization, 1999 (document reference WHO/EDM/PAR/99.5).
52.	World Health Organization. Guidelines for Drug Donations. Revised 1999. Geneva, World Health Organization, 1999 (document reference WHO/EDM/PAR/99.4).
53.	World Health Organization. Guidelines for Safe Disposal of Unwanted Pharmaceuticals in and after Emergencies. Geneva, World Health Organization, 1999 (document reference WHO/EDM/PAR/99.2).
54.	Keynote address by Director-General Dr Gro Harlem Brundtland to Ninth International Conference of Drug Regulatory Authorities. Berlin, 27 April 2000. Accessible at: http://www.who.int/director-general/speeches/1999/english/19990427_berlin.html.
55.	World Health Organization. Effective Drug Regulation: What Can Countries Do? Geneva, World Health Organization, 1999 (document reference WHO/HTP/EDM/MAC(11)/99.6).
56.	World Health Organization. Counterfeit Drugs: Guidelines for the Development of Measures to Combat Counterfeit Drugs. Geneva, World Health Organization, 1999 (document reference WHO/EDM/QSM/99.1).
57.	World Health Organization. Regulatory Situation of Herbal Medicines: Worldwide Review. Geneva, World Health Organization, 1998.
58.	World Health Organization. Counterfeit and Substandard Drugs in Myanmar and Vietnam. Geneva, World Health Organization, 1999(document reference WHO/EDM/QSM/99.3).
59.	World Health Organization. Medical products and the Internet: a Guide to Finding Reliable Information. Geneva, World Health Organization, 1999 (document reference WHO/EDM/QSM/99.4).
60.	Bensoussan A, Myers SP. Towards a Safer Choice. The Practice of Traditional Chinese Medicine in Australia. MacArthur, University of Western Sydney, 1996.
61.	Ministry of Health and Welfare, Republic of Korea. Traditional Korean Medicine Services. April 2000.
62.	The Uppsala Monitoring Centre website can be found at: http://www.who-umc.org/umc.html.
63.	World Health Organization. The Rational Use of Drugs. Report of the Conference of Experts, Nairobi, 25 - 29 November, 1985. Geneva, World Health Organization, 1987.
64.	Kamat VR, Nichter M. Monitoring product movement: an ethnographic study of pharmaceutical sales representatives in Bombay, India. In: Bennett S, McPake B, Mills A, eds. Private Health Providers in Developing Countries: Serving the Public Interest? London, Zed Press, 1997.
65.	Framework for containing resistance to antimicrobial drugs. WHO presentation at Infectious Diseases Partners Initial Meeting, US Agency for International Development, Washington DC, 16 - 17 December 1997.
66.	GASP, 1997.
67.	Laing RO, Hogerzeil HV, Ross-Degnan D. Ten recommendations to promote improved use of medicines in developing countries. Social Science and Medicine, 2000 (submitted).
68.	See http://www.who.int/medicines/ for discussion of rational drug use and related research.
69.	WHO Drug Information, 1999, 13(4): 249 - 262.
70.	De Vries TPGM et al. Impact of a short course in pharmacotherapy for undergraduate medical students. Lancet, 1995, 346: 1454 - 1457.
71.	Quick JD, Laing RO, Ross-Degnan DG. Intervention research to promote clinically effective and economically efficient use of pharmaceuticals: the International Network for the Rational Use of Drugs. Journal of Clinical Epidemiology, 1991, 44(Suppl. II): 57S - 65S.
72.	Simonsen L et al. Unsafe injections practices and transmission of bloodborne pathogens. Bulletin of the World Health Organization, 1999, 77(10): 787 - 819.
73.	Weekes LM, Brooks C. Drugs and therapeutics committees in Australia: expected and actual performance. British Journal of Clinical Pharmacology, 1996, 42: 551 - 557.
74.	World Health Organization. Public Education in Rational Drug Use. A Global Survey. Geneva, World Health Organization, 1997 (DAP Research Series No. 24. Document reference WHO/DAP/97.5.).
75.	World Health Organization. How to Investigate Drug Use in Communities. Geneva, World Health Organization, 1992(DAP Research Series No. 2. Document reference WHO/DAP/92.3.).
76.	World Health Organization. WHO Proposed Programme Budget. Geneva, World Health Organization (draft available to Member States; in press).
77.	World Health Organization. Informal Meeting on Assessment and Monitoring of National Drug Policies. Geneva, World Health Organization, 1998 (document reference DAP/98.4).
78.	Brudon P, Rainhorn J-D, Reich MR. Indicators for Monitoring National Drug Policies, 2^ndedition. Geneva, World Health Organization, 1999(document reference WHO/EDM/PAR/99.3).